ADT-OH

ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases[1][5].

Product Specifications

CAS Number

[18274-81-2]

Product Name Alternative

5- (4-Hydroxyphenyl) -3H-1,2-dithiole-3-thione; ACS 1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; FAK

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/adt-oh.html

Concentration

10mM

Purity

98.55

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

S=C1SSC(C2=CC=C(O)C=C2)=C1

Molecular Formula

C9H6OS3

Molecular Weight

226.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11 (1) :33.|[2]Yu S, et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission. Cell Death Dis. 2024 Jun 28;15 (6) :463. |[3]Xu H, et al. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer Med. 2023 Aug;12 (16) :17193-17211.|[4]Wei SW, et al. Role of the hydrogen sulfide-releasing donor ADT-OH in the regulation of mammal neural precursor cells. J Cell Physiol. 2022 Jul;237 (7) :2877-2887.|[5]Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719.